Market Place
Sourcing Support
Cabaletta Bio Reports 2025 Financials And Business Update
23 Mar 2026 //
GLOBENEWSWIRE
Cabaletta Bio Announces Proposed Public Offering of Securities
11 Jun 2025 //
GLOBENEWSWIRE
Cabaletta Bio Reports Q4 and Full Year 2024 Financial Results
31 Mar 2025 //
GLOBENEWSWIRE
Cabaletta Bio at TD Cowen 45th Annual Health Care Conference
26 Feb 2025 //
GLOBENEWSWIRE
Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum
02 Jul 2024 //
GLOBENEWSWIRE
Cabaletta`s early data signal CAR-T potential in inflammatory diseases
15 Jun 2024 //
PRESS RELEASE
Cabaletta Reports Initial CABA-201 Data In Myositis And SLE
14 Jun 2024 //
GLOBENEWSWIRE
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
29 May 2024 //
GLOBENEWSWIRE
Cabaletta Bio Reports Q1 2024 Financials, Business Update
15 May 2024 //
GLOBENEWSWIRE
Cabaletta Bio To Participate In H.C. Wainwright BioConnect Conference
13 May 2024 //
GLOBENEWSWIRE
3 Stocks with Growth Prospects in the Triple Digits
29 Apr 2024 //
AOL
Cabaletta Reports Q4 and FY23 Financial Results and Provides Business Update
21 Mar 2024 //
GLOBENEWSWIRE
Cabaletta Bio to Participate in Upcoming Investor Conferences in March
27 Feb 2024 //
GLOBENEWSWIRE
Cabaletta to Participate in Guggenheim Healthcare Talks 6th Annual Conference
31 Jan 2024 //
GLOBENEWSWIRE
Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 //
GLOBENEWSWIRE
Cabaletta Bio to Participate in 6th Annual Evercore ISI HealthCONx Conference
28 Nov 2023 //
GLOBENEWSWIRE
Cabaletta Bio Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Cellares to produce Cabaletta’s autoimmune CAR-T candidate
06 Nov 2023 //
ENDPTS
Cabaletta to Participate in Multiple Upcoming Investor Conferences in November
30 Oct 2023 //
GLOBENEWSWIRE
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
19 Sep 2023 //
GLOBENEWSWIRE
Here`s Why We`re Not Too Worried About Cabaletta Bio`s Cash Burn Situation
12 Sep 2023 //
SIMPLY WALL
Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in Sep
30 Aug 2023 //
GLOBENEWSWIRE
Cabaletta Bio Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Cabaletta Appoints Commercial Leader Shawn Tomasello to Board of Directors
24 Jul 2023 //
GLOBENEWSWIRE
Why Shares of Cabaletta Bio Are Up Tuesday
18 Jul 2023 //
FOOL
Cabaletta Bio to Present at the Jefferies Healthcare Conference
31 May 2023 //
GLOBENEWSWIRE
Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock
22 May 2023 //
GLOBENEWSWIRE
Cabaletta lands $84M from stock sale after FDA clears INDs for CD19
18 May 2023 //
ENDPTS
Cabaletta Bio Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
Cabaletta Bio to Present at the H.C. Wainwright BioConnect Conference
25 Apr 2023 //
GLOBENEWSWIRE
Cabaletta Bio to Present at 22nd Annual Needham Virtual Healthcare Conference
13 Apr 2023 //
GLOBENEWSWIRE
Cabaletta Bio Reports Fourth Quarter and Full Year 2022 Financial Results
16 Mar 2023 //
GLOBENEWSWIRE
Cabaletta Bio to Present at the Cowen 43rd Annual Health Care Conference
28 Feb 2023 //
GLOBENEWSWIRE
Cabaletta Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
05 Jan 2023 //
GLOBENEWSWIRE
Cabaletta Bio Announces $35 Million Offering
08 Dec 2022 //
GLOBENEWSWIRE
Cabaletta Bio to Present at the 5th Annual Evercore ISI HealthCONx Conference
22 Nov 2022 //
GLOBENEWSWIRE
IASO & Cabaletta Announce License Agreement for Clinically Validated CD19 Binder
11 Oct 2022 //
PRNEWSWIRE
Cabaletta Bio Announces CABA-201,Newly CD19-Targeting CAR T Cell Therapy
11 Oct 2022 //
GLOBENEWSWIRE
Cabaletta Bio to Present at the 29th Annual Congress of the European Society
06 Oct 2022 //
GLOBENEWSWIRE
Cabaletta Bio to Present at the Chardan 6th Annual Genetic Medicines Conference
26 Sep 2022 //
GLOBENEWSWIRE
Cabaletta Bio Presents New Interim Data from the DesCAARTes™ Ph1 Trial
10 Sep 2022 //
GLOBENEWSWIRE
Cabaletta Bio to Present Data on DesCAARTes Trialat at the 31st EADV Congress
29 Aug 2022 //
GLOBENEWSWIRE
Cabaletta Bio Reports Q2 2022 Rusult and Provides Business Update
11 Aug 2022 //
GLOBENEWSWIRE
Cabaletta Bio Presents Updated Interim DesCAARTes Trial Phase 1 Data
18 May 2022 //
GLOBENEWSWIRE
Cabaletta Bio to Present at the H.C. Wainwright Global Investment Conference
17 May 2022 //
GLOBENEWSWIRE
Cabaletta Bio Reports First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
Cabaletta Bio to Present DSG3-CAART Clinical, MuSK-CAART Preclinical Data
02 May 2022 //
GLOBENEWSWIRE
Cabaletta Bio to Present at 21st Annual Needham Virtual Healthcare Conference
06 Apr 2022 //
GLOBENEWSWIRE
Cabaletta Bio Reports Q4 and FY 2021 Financial Results
17 Mar 2022 //
GLOBENEWSWIRE
U.S. FDA Grants Cabaletta Bio Fast Track Designation for MuSK-CAART
01 Mar 2022 //
GLOBENEWSWIRE
Cabaletta Bio to Participate in Cowen Virtual 42nd Annual Health Care Conference
28 Feb 2022 //
GLOBENEWSWIRE
Cabaletta Bio Reports Top-line Biologic Activity Data Two Lowest Dose Cohorts
14 Dec 2021 //
GLOBENEWSWIRE
Cabaletta Expands Executive Leadership Team with Appointments of Samik Basu, M.D
09 Nov 2021 //
GLOBENEWSWIRE
Cabaletta Bio Reports Third Quarter 2021 Financial Results
01 Nov 2021 //
GLOBENEWSWIRE
Cabaletta Bio Reports Clinical Data from the Third Dose Cohort in DesCAARTes™
01 Nov 2021 //
GLOBENEWSWIRE
Cabaletta Bio to Present at the Chardan 5th Annual Genetic Conference
28 Sep 2021 //
GLOBENEWSWIRE
Cabaletta Bio Announces Appointment of Michael Gerard as General Counsel
07 Sep 2021 //
GLOBENEWSWIRE
Cabaletta Bio Reports Clinical Data from the Second Dose in DesCAARTes™ Trial
18 Aug 2021 //
GLOBENEWSWIRE
Cabaletta Bio Reports Second Quarter 2021 Financial Results
05 Aug 2021 //
GLOBENEWSWIRE
Cabaletta Bio Reports Safety Data from the First Dose Cohort in DesCAARTes Trial
04 May 2021 //
GLOBENEWSWIRE
